Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (NASDAQ: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Understanding (MOU) to advance drug development for lysosomal diseases (LDs) and improve the quality of life for those impacted by these conditions.
The MOU outlines a strategic partnership aimed at leveraging both organizations' strengths in genetic and real-world data (RWD) to overcome barriers in developing safe and effective therapies for LDs.
C-Path forms collaborative work groups comprised of diverse stakeholders to identify specific barriers to developing safe and effective therapies for a given disease. These focus groups then create tools and solutions that help drug developers overcome those barriers.
CENTOGENE is a global leader in genomic and multiomic testing services, utilizing advanced sequencing technologies to accelerate the diagnosis and development of treatments for rare and neurodegenerative diseases. Since 2006, CENTOGENE has generated data-driven insights from its Diagnostics segment – capturing the data in the CENTOGENE Biodatabank, the world’s largest real-world integrated multiomic data repository in rare and neurodegenerative diseases with over 850,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent.
CNTG shares grabbed six cents, or 15.6%, to 46 cents.
